Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 20 Issue 6, June 2023

Gastroenterology and the environment, inspired by the Editorial on p339, the Perspective on p399 and the Comment on p340.

Cover design: Laura Marshall.

Editorial

  • The health-care sector produces significant amounts of waste and greenhouse gas emissions. In turn, environmental damage can have a negative effect on health, including gastrointestinal health. Two articles in this month’s issue prompt us to reflect upon the connections between gastrointestinal health, the health-care sector and the environment.

    Editorial

    Advertisement

Top of page ⤴

Comment

  • A new report from the World Health Organization has evaluated the risks of dietary exposure to nanoplastic and microplastic particles (NMPs) to human health. Although challenges in the detection of NMPs in food and beverages remain, it is clear that humans are being exposed. Presently, no convincing evidence of adverse health effects are found, but major knowledge gaps remain.

    • Luc J. W. van der Laan
    • Thijs Bosker
    • Willie J. G. M. Peijnenburg
    Comment
  • Barrett oesophagus is not detected before its progression to oesophageal adenocarcinoma in over one-half of patients, and improvements in screening for Barrett oesophagus in primary care could substantially reduce mortality associated with this cancer. Advances in screening technology will help, but collaboration of gastroenterologists with primary care providers is essential.

    • Arvind J. Trindade
    • Nicholas J. Shaheen
    Comment
Top of page ⤴

Research Highlights

Top of page ⤴

News & Views

  • A prospective study suggests that the risk of liver fibrosis with methotrexate treatment has been overestimated. The findings suggest the need to reconsider the intensive strategies and the screening tools that are recommended for monitoring liver fibrosis in patients receiving methotrexate.

    • Raul J. Andrade
    • Einar S. Björnsson
    News & Views
Top of page ⤴

Reviews

Top of page ⤴

Perspectives

Top of page ⤴

Search

Quick links